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Abstract
Background: Loiasis, an often-neglected tropical disease, is a threat to the success of lymphatic filariasis and
onchocerciasis elimination programmes in rainforest areas of the central and western Africa. Its control and even its
elimination might be possible through the use of a safe macrofilaricide, a prophylactic drug, or perhaps a vaccine.
This present study evaluated the effect of flubendazole (FLBZ) on the development of Loa loa L3 in vitro and in
vivo.
Methods: Infective stages of L. loa were isolated and co-cultured in Dulbecco’s Modified Eagle’s Medium in the
presence of monkey kidney epithelial cells (LLC-MK2) feeder cells. FLBZ and its principal metabolites, reduced
flubendazole (RFLBZ) and hydrolyzed flubendazole (HFLBZ), were screened in vitro at concentrations 0.05, 0.1, 0.5,
1 and 10 μg/ml. The viability of the parasites was assessed microscopically daily for 15 days. For in vivo study, a
total of 48 CcR3 KO mice were infected subcutaneously with 200 L. loa L3 and treated with 10 mg/kg FLBZ once
daily for 5 consecutive days. Twenty-four animals were used as control and received L3 and vehicle. They were
dissected at 5, 10, 15 and 20 days post-treatment for worm recovery.
Results: The motility of L3 larvae in vitro was reduced from the second day of incubation with drugs at in vivo
plasma concentration levels, with a strong correlation found between reduced motility and increased drug
concentration (Spearman’s rho = -0.9, P < 0.0001). Except for HFLBZ (0.05 μg/ml and 0.01 μg/ml), all concentrations
of FLBZ, HFLBZ and RFLBZ interrupted the moulting of L. loa infective larvae to L4. In vivo, regardless of the
experimental group, there was a decrease in parasite recovery with time. However, at each time point this
reduction was more pronounced in the group of animals treated with FLBZ compared to equivalent control.
Parasites were recovered from the flubendazole-treated groups only on day 5 post-inoculation at an average rate
of 2.1%, a value significantly lower (Mann-Whitney U-test, U = 28, P = 0.0156) than the average of 31.1% recovered
from the control group.
Conclusions: This study reveals the ability of flubendazole to inhibit the development of L. loa L3 both in vitro
and in vivo, and in addition validates the importance of in vitro and animal models of L. loa as tools for the
development of drugs against loiasis.
Keywords: Flubendazole, Loa loa L3, Moulting, Motility, In vitro, In vivo
* Correspondence: samwandji@gmail.com; swanji@yahoo.fr
†Fanny Fri Fombad and Abdel Jelil Njouendou contributed equally to this
work.
1Parasites and Vectors Biology Research Unit (PAVBRU), Department of
Microbiology and Parasitology, Faculty of Science, University of Buea, Buea,
Cameroon
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fombad et al. Parasites & Vectors           (2019) 12:14 
https://doi.org/10.1186/s13071-018-3282-x
Background
Loiasis, a neglected tropical disease (NTD), is endemic
in the rainforest areas of the central and western Africa
[1], where it generally causes minimal pathology [2] that
includes localized mild to moderate pruritus, edema and
occasional subconjunctival migrations of the adult worm
[3]. It is transmitted by blood sucking Chrysops flies in
which the Loa loa microfilariae (mf) develop into infect-
ive larvae (L3) and are then inoculated into a human
host during the vector’s second blood meal. The infect-
ive larvae take 6–12 months to develop into adult
worms in the human host; adult worms can survive for
more than a decade, during which they migrate through
subcutaneous tissues and their females releasing micro-
filariae into the circulation.
Loiasis has gained prominent attention in the past
twenty years because of the cases of severe adverse events
(SAEs) occurring in individuals with high microfilaremia
treated with ivermectin during mass drug administration
(MDA) campaigns in sub-Saharan Africa [4, 5]. High mi-
crofilarial load (> 8000 mf/ml) has been reported to be as-
sociated with encephalopathy post-ivermectin treatment
[4], and is associated with a rapid decrease of circulating
mf [6]. This risk of side effects has made MDA with iver-
mectin unacceptable in areas of co-endemicity where the
L. loa prevalence exceeds 20% [7], and has therefore com-
promised onchocerciasis elimination efforts in those areas
[8]. Unfortunately, there is currently no recommended
drug for the control of loiasis. Diethylcarbamazine (DEC),
which was used to treat loiasis, has been reported to in-
duce SAEs in a manner similar to its effect in individuals
infected with Onchocerca volvulus [9], a filaria often
co-endemic in loiasis endemic areas. Reduction in the ad-
verse effects of loiasis would be accelerated if there was a
safe macrofilaricidal drug. It has been shown recently that
benzimidazole flubendazole can block the transmission of
filariae by inhibiting the development of the microfilarial
stages of Brugia into L3 in an appropriate vector [10]. To
date there is no information concerning the effect of this,
or other, drugs on the development of L3 into L4. The
availability of an in vitro, and an in vivo, platform where
various stages of L. loa and other filarial species, such as
Mansonella perstans, can develop into L4 [11–13] would
offer an opportunity to obtain such information. To sup-
port development of such a platform, we have here
assessed the effect of flubendazole (FLBZ) on the develop-
ment of L. loa L3 in vitro and in vivo. The results will help
to extend the knowledge on the spectrum of filaricidal
activities of FLBZ.
Methods
Production of L. loa L3 larvae
Loa loa L3 were obtained from dissected Chrysops flies
that had previously fed on a consenting microfilariae
positive individual at Ediki Forest (South West region,
Cameroon) using a previously described protocol [11].
Briefly, engorged Chrysops were kept in captivity for 12
days to allow development to the infective stage L3, with
the flies then being dissected in Petri dishes containing
RPMI 1640 medium (Sigma-Aldrich, St. Louis, USA).
The head, thorax and abdomen were teased apart and
separated into three different Petri dishes, and all the in-
sect tissue incubated for 20 min to allow migration of any
L3 larvae present. A sterile pipette was used to isolate and
remove the larvae from each Petri dish, which were then
pooled in shallow convex glass dishes followed by transfer
into 15 ml centrifuge tubes (Corning, Kennebunk-ME,
USA) for purification. Only L3 harvested from the head
(where more mature larvae are expected to be found)
were used in this present study. The remaining larvae
were frozen for future use. The isolated L3 were washed
in RPMI 1640 and this suspension concentrated to less
than 1 ml by slowly layering it onto the surface of a 15 ml
centrifuge tube containing stock iso-osmotic Percoll® (GE
Healthcare, Pharmacia, Uppsala, Sweden) and centrifuged
(Humax 14k human, Wiesbaden, Germany) at 300× g for
10 min.
In vitro culture and assessment of parasite viability
Flubendazole and its principal metabolites, reduced fluben-
dazole (RFLBZ) and hydrolyzed flubendazole (HFLBZ),
were obtained from Epichem Pty Ltd (Murdoch, Australia).
Stock solution of each drug was prepared at 1 mg/ml in
DMSO, and a 10 μl aliquot transferred into a complete cul-
ture medium to achieve 10 ml at the concentration of 10
μg/ml. Further dilutions were made in culture medium
containing 0.1% DMSO to achieve the final concentrations
1.0, 0.5, 0.1 and 0.05 μg/ml.
Parasites were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco by Life Technologies, Cergy-
Pontoise, France) as this medium was previously shown
to promote survival and moulting of L. loa L3 in vitro
[13]. This basic medium was supplemented with 100
U/ml penicillin, 100 μg/ml streptomycin, 200 μg/ml
neomycin (Gibco by Life Technologies, Cergy-Pontoise,
France), 10 μg/ml fluconazole (Sigma-Aldrich, St Louis,
USA) and 10% fetal bovine serum (Lonza, Verviers,
Belgium). Flat bottom culture plates (48-well) with lids
(Corning, USA), pre-coated with LLC-MK2 as previously
described [12, 13], were loaded as follows: aliquots of 400
μl of the drug in culture medium at a given concentration,
or 0.1% DMSO (negative control), were loaded in each
well of the 48-well plate. 10 μl of DMEM containing 15–
20 infective larvae were added in each well. Six replicates
were created for each drug concentration. The plate was
incubated at 37 °C and 5% CO2 in a CO2 incubator (CO2
series Shel Lab, Cornelius, USA), and the L3 motility and
moulting scored by two independent trained scientists
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(blinded to the nature of the treatment) monitored daily
for 15 days as previously described [12, 13].
The viability of the parasites was evaluated using their
motility as the primary indicator. The motility was scored
on a 4-point scale: 0, no movement or immotile; 1, inter-
mittent shaking of head and tail; 2, sluggish (shaking of
the whole worm whilst the worms remains in one location
in the well); 3, vigorous movement (shaking of the whole
worm and with migration from one location in the well to
another). The % motility variable was computed based on
the scoring system described above, and using the follow-
ing formula:
Motility %ð Þ ¼
P
SiNi
3:
P
Ni
 100
where Si is the score of point scale i and Ni is the total
number of worms at a point scale i [12, 13].
Experimental animals and in vivo studies
Experimental CcR3 BALB/c knockout (KO) mice, 5–6
weeks of age, were shipped from the Institute of Medical
Microbiology, Immunology and Parasitology (IMMIP),
University Hospital Bonn, Germany, to the Research
Foundation for Tropical Diseases and the Environment
(REFOTDE), Buea, Cameroon. This strain of animals was
selected because eosinophil recruitment was previously
shown to be involved in parasite clearing after infection
[11]. They were reared and maintained in the laboratory
as described previously [11]. Mice were housed in patho-
gen free cages at the Research Foundation for Tropical
Disease and Environment (REFOTDE). Animals were kept
at 22 °C and a 12:12 h day:night light cycle. Water and
food were provided with a change of autoclaved sawdust
bedding twice weekly.
A total of 48 mice (24 in the test group + 24 in the
vehicle only group) were used. The L3 obtained from
Chrysops dissections were concentrated at 200 L3 per
100 μl RPMI 1640 medium. Infection was carried out by
subcutaneous injection at the nape of the neck using a 1
ml insulin syringe. Efficiency of inoculation was con-
firmed by needle washout to check for any remaining
parasites.
FLBZ suspension, given subcutaneously, was first
homogenised in demineralised water with 0.1% Tween
80 using a Polytron disperser then made up to volume
with hydroxyethylcellulose (HEC). The vehicle for the
FLBZ suspension was 0.5% w/v HEC in demineralized
water containing 0.1% Tween 80. Mice were ear-notched
for unique identification and were randomly assigned to
test or control groups. Flubendazole was administered
subcutaneously by injection of a single dose (10 mg/kg)
to all animals in the test group, and 100 μl of its vehicle
was administered to each animal in the control group
and given 24 h after infection with L3.
Fourteen animals (7 tests and 7 controls) were dissected
on each of days 5 and 15 post-drug administration, whilst
10 (5 tests and 5 controls) were dissected on each of days
10 and 20 post-drug administration. Mice were euthanized
by exposure to an overdose of CO2 [14]. Cardiac blood
was first collected by syringe and placed in un-coated 1.5
ml microcentrifuge tubes, and the resulting sera removed
and stored at -80 °C for further analysis. A range of organs
were gently excised and placed in separate Petri dishes
containing RPMI 1640 medium. Muscle tissues were
teased gently to ease worm migration into the medium.
The sample containing Petri dishes were incubated at
37 °C for 1 h for migration of the L. loa worms and
then under dissecting microscope (Leica, MDG33/
10450123, Singapore) for presence of parasites. The
number of worms recovered from the different tissues
was recorded on the dissection-recording sheet.
Data analysis
Raw data were recorded on spreadsheets, and the mo-
tility responses generated. Data were further loaded
into R version 3.4.1 [15] for statistical analysis and
graphical displays. The mean values, standard deviation
and other statistical parameters of final records for both
in vitro and in vivo experiments were determined for
each experimental group (drug concentration for in
vitro). The effect of the drugs on the motility of para-
sites was also assessed by comparing the respective area
under the curve (AUC) results using either the first 9
days of culture or 30 days as the time periods for in
vivo studies. These end time-points were selected to re-
flect the commencement of moulting, generally charac-
terised by the reduction in motility regardless of the
presence of a drug. The variable T90, defined as the
duration at which 90% of the worms were still fully
active in the well, was also computed. The values of
AUC and T90 were expressed as the mean ± standard
deviation. The lower the value of AUC or T90, the
higher the activity of the drug at the concentration or
dose indicated. The effects of drug concentrations on
parasite viability were compared using non-parametric
tests. The Kruskal-Wallis one-way non-parametric
ANOVA was used to assess the global significant differ-
ences between the median AUC of the various concen-
trations of each drug. When a difference was detected,
Spearman’s rank correlation was used to assess the as-
sociation between the drug concentration and the AUC
of the parasite motility within 9 incubation days. The
distribution of median AUC between treated and con-
trol groups for the in vivo experiment was compared
using the Mann-Whitney U-test. Statistical tests were
interpreted using a 5% significance level.
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Results
In vitro studies
Effect of flubendazole and derivatives on parasites viability
Loa loa infective larvae remained viable in control wells
culture with optimal motility (close to 100%) within the
first 9 days of culture, then declined, however remained
above 50% (Additional file 1: Table S1, Fig. 1) for 21
days incubation. The motility of L3 larvae in vitro was
reduced after the second day of incubation with FLBZ
at concentrations between 0.05–10 μg/ml; this effect
increased with drug concentration. At day 5, the per-
cent motility was 100% in the control (DMSO, 0.1%)
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Fig. 1 Effects of flubendazole and its derivatives on the motility of L. loa L3. a Flubendazole (FLBZ). b Hydrolysed flubendazole (HFLBZ). c Reduced
flubendazole (RFLBZ)
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compared with less than 40% in treated samples (FLBZ,
10 μg/ml); the latter gradually reduced to a value close
to 0% by day 15 (Fig. 1a).
The hydrolyzed derivative of flubendazole (HFLBZ)
did not significantly affect parasite motility at concentra-
tions 0.05 or 0.1 μg/ml, compared to the control
(DMSO, 0.1%). At the highest drug concentrations (0.5,
1 and 10 μg/ml) however, marked reduction in motility
was observed on the third incubation day. Only 10% par-
asites remain motile by day 15 at 10 μg/ml (Fig. 1b).
Reduced flubendazole also induced reductions in para-
site motility regardless of the concentration, and these
were generally lower than those seen in control at each
time point (Fig. 1c). Although motility reduction was
also concentration-dependent, the degree of reduction
was lower than those observed with native FLBZ. On
day 15, more than 30% of parasites remained actively
motile irrespective of the drug concentration; in
addition, the motility in the control cultures (0.1%
DMSO) also decreased after 9 days of culture.
Effects of the concentrations on the activities of
flubendazole and its derivatives in vitro
The AUC values for the first 9 days, together with the
T90, of each of the three drugs were used to compare the
effect of their different concentrations on the parasite
motility (Table 1 and Table 2, respectively). At concen-
trations between 0.05–10 μg/ml, the average AUC
ranged between 90.9–58.7, 99.6–78.1 and 91.7–85.7 for
FLBZ, HFLBZ and RFLBZ, respectively (Table 1). The
Kruskal-Wallis test indicated that irrespective of the
drug, the reduction in average AUC varied significantly
between concentrations. Interestingly, Spearman’s rank
test indicated that the increase in drug concentration is
strongly associated with the reduction in AUC of para-
site motility.
The same pattern of result was obtained when consid-
ering the average T90 values of the various drugs against
the experimental concentrations (Table 2), and when
concentrations were converted to the logarithmic scale
(Additional file 2: Figure S1). At concentrations between
0.05–10 μg/ml, the average T90 ranged between 5.10–
1.10, 10.46–1.90 and 5.52–2.85 for FLBZ, HFLBZ and
RFLBZ, respectively (Table 2). Again, the Kruskal-Wallis
test indicated that independent of the drug used, the
reduction in average T90 significantly varied between
concentrations, and high negative correlations were also
found between the average T90 and the concentrations
of each drug.
In vitro effect of flubendazole and its derivatives on
moulting of infective L. loa larvae
Except for HFLBZ 0.05 μg/ml and 0.01 μg/ml, all con-
centrations of FLBZ, HFLBZ and RFLBZ halted the
molting of L. loa infective larvae to L4. The moulting
rate ranged from 23.6 ± 8.8% (DMSO, 0.1%) to 0% for
parasites exposed to drugs (Table 3, Additional file 3:
Figure S2).
Table 1 Relationship between average AUC and the concentrations of the drugs tested
Drug Concentration
(μg/ml)
Average
AUC ± SD
Kruskal-Wallis rank sum test Spearman’s rank correlation
χ2 df P-value rho P-value
DMSO (0.1%) 99.5 ± 0.4 – – – – –
FLBZ 0.05 90.9 ± 0.9 19.286 5 0.00170 -0.946 <0.0001
0.1 92.7 ± 0.6
0.5 84.8 ± 2.3
1 74.8 ± 0.7
10 58.7 ± 0.7
HFLBZ 0.05 99.6 ± 0.3 17.662 5 0.00340 -0.908 <0.0001
0.1 98.7 ± 0.4
0.5 95.7 ± 0.7
1 90.8 ± 1.4
10 78.1 ± 0.5
RFLBZ 0.05 91.7 ± 2.7 18.784 5 0.00211 -0.950 <0.0001
0.1 92.7 ± 0.8
0.5 89.7 ± 0.9
1 87.2 ± 0.6
10 85.7 ± 0.9
Abbreviations: AUC area under the curve, DMSO dimethylsulfoxide, FLBZ flubendazole, HFLBZ hydrolysed flubendazole, RFLBZ reduced flubendazole, SD
standard deviation
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In vivo studies in the CcR3 KO mice model
Parasites were recovered from various organs of experi-
mental animals and counted (Additional file 4: Table
S2). The major sites of worm recovery were the subcuta-
neous and muscle tissue. The average percentage worm
recovery and other statistical parameters of the two ex-
perimental groups of animals within 30 days are provided
in Table 4. Regardless of the treatment group, there were
decreases in parasite recovery with time. However, this de-
crease was more pronounced in the group of animals
treated with FLBZ than with the control at each time
point. In the FLBZ-treated group, parasites were recov-
ered only on day 5 post-inoculation at an average rate of
2.1%. This value was significantly lower (Mann-Whitney
U-test, U = 28, P = 0.0156) than the average of 31.1% re-
covered in the control group. The difference between the
AUC for both groups presented in Table 4 and illustrated
in Fig. 2 were also statistically significant (Mann-Whitney
U-test, U = 4, P = 0.01052).
Discussion
Loiasis remains an important public health issue, and
treatment options are limited due to severe adverse events
[4, 5]. However, it has been shown that FLBZ, know essen-
tially as a macrofilaricidal agent drug [16, 17], exhibits lit-
tle or no microfilaridal activity against several filarial
species, such as Brugia pahangi [18], Onchocerca lienalis
[19] and L. loa [20], and its capacity in eliminating adult
worms has been elucidated in many studies for filarial spe-
cies such as B. pahangi [18, 21], Breinlia booliati [22] and
Onchocerca ochengi [23]. In this study, we showed that
FLBZ reduces worm motility from 80.5% to 14.5% by 9
days after incubation at concentrations of 0.05–10 μg/ml,
using the recently published filarial in vitro culture system
Table 2 Relationship between average T90 and the concentrations of the drugs tested
Drug Concentration
(μg/ml)
Average
T90 ± SD
Kruskal-Wallis rank sum test Spearman’s rank correlation
χ2 df P-value rho P-value
DMSO (0.1%) 11.08 ± 0.35 – – – – –
FLBZ 0.05 5.10 ± 0.1 18.974 5 0.001944 -0.970 <0.0001
0.1 5.05 ± 0.08
0.5 3.15 ± 0.66
1 1.97 ± 0.06
10 1.10 ± 0.14
HFLBZ 0.05 10.46 ± 0.18 19.043 5 0.001887 -0.974 <0.0001
0.1 10.20 ± 0.35
0.5 7.21 ± 0.63
1 5.03 ± 0.36
10 1.90 ± 0.14
RFLBZ 0.05 5.52 ± 1.01 18.506 5 0.002374 -0.934 <0.0001
0.1 5.93 ± 0.33
0.5 4.87 ± 0.28
1 3.54 ± 0.25
10 2.85 ± 0.21
Abbreviations: DMSO dimethylsulfoxide, FLBZ flubendazole, HFLBZ hydrolysed flubendazole, RFLBZ reduced flubendazole, SD standard deviation, T90 Mean duration
at which 90% of worm motility were scored 3
Table 3 Percentage moulted parasites in presence of drugs at
different concentrations
Drug Concentration (μg/ml) Average moulting rate ± SD (%)
DMSO (0.1%) 23.6 ± 8.8
FLBZ 0.05 0
0.1 0
0.5 0
1 0
10 0
HFLBZ 0.05 14.3 ± 6.0
0.1 2.4 ± 2.4
0.5 0
1 0
10 0
RFLBZ 0.05 0
0.1 0
0.5 0
1 0
10 0
Abbreviation: SD standard deviation
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that has been shown to promote development and
moulting of infective stages of L. loa [13] and M. per-
stans [12]. Reduction in motility was found to be
concentration-dependent. Similar activities were observed
with the reduced metabolite of FLBZ with motility reduc-
tion of 82.6% to 75.4% by day 9 at concentrations of 0.05–
10 μg/ml. Previous investigation of the pharmacokinetics
of FLBZ and its main metabolites has revealed that their
pharmacokinetics parameters are species-dependent. In
lambs and adult sheep, FLBZ is present at very low con-
centrations (Cmax = 0.04 μg/ml), close to the lowest con-
centration tested in this study, while RFLBZ is identified
as the main metabolite (Cmax = 0.14 μg/ml), and HFLBZ
is present in trace amounts [24, 25], with a Cmax far
below the lowest concentration tested here. The reduced
metabolite of flubendazole was also reported to be the
major metabolite in mice [26]. In pigs, however, the hy-
drolysed metabolite of flubendazole represent 97% of the
total plasmatic drug after oral administration [27]. In rats
and jirds, a completely different profile has been reported,
with the parental drug being the major drug detected,
followed by its hydrolysed derivative against trace amount
of RFLBZ [28].
Previous studies with a range of helminths indicated
that RFLBZ is the main, and perhaps the sole, active
metabolite, with HFLBZ having no anthelminthic activ-
ity [29–31]. However, our findings here, in addition to
other recent observations [20], indicate that FLBZ and
its derivatives display heterogenic patterns of activity
depending on the species of helminth and the stage be-
ing considered. At concentrations of 1 μg/ml and
above, there was a clear reduction in L. loa larvae mo-
tility with FLBZ, and with its reduced metabolite.
HFLBZ was also active, and at comparable concentra-
tions, this metabolite seen to be more active in vitro
(CR50 = 8.1 μg/ml) against microfilaria of the same spe-
cies than RFLBZ (CR50 = 17.5 μg/ml) and FLBZ (CR50
= 21 μg/ml) [20]. In addition, at these concentrations
worms did not appear to moult in the presence of FLBZ
and RFLBZ, but did in wells treated with HFLBZ; the
percentage of moulted worms in these decreased as a
result of increase in drug concentration. These latter
observations are not easily interpreted but may be due
the parallel effects of stress and survival attempts by
these worms under these conditions; the true reason
Table 4 Summary statistics of worm recovery in CcR3 KO mice within 30 days
Experimental groups Statistics Recovery time (days) AUC (%)
5 10 15 20
Control (n = 7)a Mean 31.1 21.5 8.8 16.5 23.9
Geometric mean 22.4 11.8 4.2 7.1 21.3
Median 35.5 14.5 5.5 12.0 20.8
SD 18.05 26.1 9.6 19.6 11.9
10 mg/kg FLBZ (s.c., single
dose, n = 7)a
Mean 2.1 0 0 0 8.7
Median 2.5 0 0 0 8.8
Geometric mean 1.5 0 0 0 8.7
SD 2.1 0 0 0 0.4
Mann-Whitney rank sum test U 28 – – – 4
P-value 0.0156 – – – 0.01052
Abbreviations: AUC area under the curve, n number of animal per group, FLBZ flubendazole, – not computed, SD standard deviation
aSeven animals were dissected at each time point except on days 10 and 20, where 5 were dissected
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would require further investigation. These present ob-
servations contrast with previous findings on microfil-
ariae of L. loa, where it was observed that the
inhibitory effect of parasite viability was more pro-
nounced in the presence of HFLB rather than FLBZ
and its reduced metabolite [20]. The motility of the
control cultures was found to be reduced after the 9th
day of culture; this period coincided with the starting
point of moulting and corroborated our previous obser-
vations [13].
Our result here concerning the inhibition of motility
in vitro indicate that FLBZ and its major metabolites
are not acutely toxic to the developing stages of L. loa.
However, arguably the most important effect observed
in the present study is the inhibition of moulting, and
the consequent prevention of the development of in-
fective stages to the adult form. Previous studies on the
enzymology of the cuticle in parasitic nematodes have
highlighted the inhibition of enzymes involved in para-
site escheatment as promising approach for drug/vac-
cine development [32]. Thus, in addition in the
inhibition of motility, the inhibition of moulting is a
likely useful indicator for determining the potential of
filaricides as agents for blocking disease transmission.
The in vivo findings in this present study added import-
ant information regarding the efficacy of flubendazole and
its metabolites. Following administration of a single dose
of FLBZ (10 mg/kg) to infected mice, parasites were re-
covered only on day 5 post-inoculation at an average rate
of 2.1%. The recovery rate in the flubendazole-treated
group was significantly lower than the average of 31.1%
recovered in the control group, indicating that this drug
inhibits parasite development. A difference in parasite sur-
vival between the two groups of animals was also con-
firmed by the difference in their AUCs. As observed in
vitro, the residual FLBZ and its major metabolite were
shown to be more active in inhibiting both parasite
growth and survival; this underscores the possibility that
this agent may play an important role in blocking parasite
development in vivo.
Conclusions
This study has revealed that FLBZ can inhibit the de-
velopment of L. loa L3 both in vitro and in vivo. To
our knowledge, this is the first time that FLBZ has
been demonstrated to inhibit the moulting of infective
larvae of L. loa into L4. These findings highlight the
potential of FLBZ in blocking transmission of L. loa.
The study also demonstrates the added value of using
both in vitro and in vivo platforms when assessing the
efficacy of drugs on developing stages of L. loa, and
thus provide an additional approach for the screening
of filaricides.
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